Financhill
Sell
48

ARAY Quote, Financials, Valuation and Earnings

Last price:
$2.14
Seasonality move :
5.99%
Day range:
$2.07 - $2.17
52-week range:
$1.40 - $2.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.48x
P/B ratio:
4.74x
Volume:
413.6K
Avg. volume:
646.3K
1-year change:
-24.47%
Market cap:
$214.2M
Revenue:
$446.6M
EPS (TTM):
-$0.17

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARAY
Accuray
$110.4M -$0.04 2.91% -60% $6.13
BAX
Baxter International
$2.7B $0.52 -62.77% 8.2% $40.08
BSX
Boston Scientific
$4.4B $0.66 15.3% 94.72% $100.08
CATX
Perspective Therapeutics
$257.8K -$0.26 -- -70.12% $16.15
HAE
Haemonetics
$352.9M $1.17 5.26% 92.62% $110.80
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARAY
Accuray
$2.13 $6.13 $214.2M -- $0.00 0% 0.48x
BAX
Baxter International
$29.59 $40.08 $15.1B 147.95x $0.17 3.52% 0.87x
BSX
Boston Scientific
$95.95 $100.08 $141.4B 79.30x $0.00 0% 8.94x
CATX
Perspective Therapeutics
$3.53 $16.15 $238.6M -- $0.00 0% 19.06x
HAE
Haemonetics
$78.10 $110.80 $3.9B 32.41x $0.00 0% 2.95x
XTNT
Xtant Medical Holdings
$0.47 -- $65M -- $0.00 0% 0.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARAY
Accuray
79.01% 2.022 94.17% 0.75x
BAX
Baxter International
62.17% 0.636 66.5% 0.51x
BSX
Boston Scientific
34.45% 0.507 8.79% 0.85x
CATX
Perspective Therapeutics
-- -3.977 -- --
HAE
Haemonetics
58.23% 0.862 30.25% 1.87x
XTNT
Xtant Medical Holdings
43.2% 0.300 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARAY
Accuray
$34.5M -$2.1M -7.54% -35.94% -0.37% -$8.4M
BAX
Baxter International
$1B $150M 0.49% 1.33% 6.3% $229M
BSX
Boston Scientific
$2.9B $718M 5.95% 8.91% 17.77% $698M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
HAE
Haemonetics
$187.4M $51.7M 6.54% 13.51% 14.96% $39.4M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Accuray vs. Competitors

  • Which has Higher Returns ARAY or BAX?

    Baxter International has a net margin of -3.89% compared to Accuray's net margin of 5.19%. Accuray's return on equity of -35.94% beat Baxter International's return on equity of 1.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    33.95% -$0.04 $215.5M
    BAX
    Baxter International
    38.27% $0.27 $20.9B
  • What do Analysts Say About ARAY or BAX?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 187.56%. On the other hand Baxter International has an analysts' consensus of $40.08 which suggests that it could grow by 35.47%. Given that Accuray has higher upside potential than Baxter International, analysts believe Accuray is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    BAX
    Baxter International
    3 12 1
  • Is ARAY or BAX More Risky?

    Accuray has a beta of 1.468, which suggesting that the stock is 46.785% more volatile than S&P 500. In comparison Baxter International has a beta of 0.596, suggesting its less volatile than the S&P 500 by 40.4%.

  • Which is a Better Dividend Stock ARAY or BAX?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.52% to investors and pays a quarterly dividend of $0.17 per share. Accuray pays -- of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARAY or BAX?

    Accuray quarterly revenues are $101.5M, which are smaller than Baxter International quarterly revenues of $2.7B. Accuray's net income of -$4M is lower than Baxter International's net income of $140M. Notably, Accuray's price-to-earnings ratio is -- while Baxter International's PE ratio is 147.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.48x versus 0.87x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.48x -- $101.5M -$4M
    BAX
    Baxter International
    0.87x 147.95x $2.7B $140M
  • Which has Higher Returns ARAY or BSX?

    Boston Scientific has a net margin of -3.89% compared to Accuray's net margin of 11.12%. Accuray's return on equity of -35.94% beat Boston Scientific's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    33.95% -$0.04 $215.5M
    BSX
    Boston Scientific
    68.83% $0.32 $31.8B
  • What do Analysts Say About ARAY or BSX?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 187.56%. On the other hand Boston Scientific has an analysts' consensus of $100.08 which suggests that it could grow by 4.31%. Given that Accuray has higher upside potential than Boston Scientific, analysts believe Accuray is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    BSX
    Boston Scientific
    22 5 0
  • Is ARAY or BSX More Risky?

    Accuray has a beta of 1.468, which suggesting that the stock is 46.785% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

  • Which is a Better Dividend Stock ARAY or BSX?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARAY or BSX?

    Accuray quarterly revenues are $101.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Accuray's net income of -$4M is lower than Boston Scientific's net income of $468M. Notably, Accuray's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 79.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.48x versus 8.94x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.48x -- $101.5M -$4M
    BSX
    Boston Scientific
    8.94x 79.30x $4.2B $468M
  • Which has Higher Returns ARAY or CATX?

    Perspective Therapeutics has a net margin of -3.89% compared to Accuray's net margin of --. Accuray's return on equity of -35.94% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    33.95% -$0.04 $215.5M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About ARAY or CATX?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 187.56%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Accuray, analysts believe Perspective Therapeutics is more attractive than Accuray.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    CATX
    Perspective Therapeutics
    8 1 0
  • Is ARAY or CATX More Risky?

    Accuray has a beta of 1.468, which suggesting that the stock is 46.785% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

  • Which is a Better Dividend Stock ARAY or CATX?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or CATX?

    Accuray quarterly revenues are $101.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Accuray's net income of -$4M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Accuray's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.48x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.48x -- $101.5M -$4M
    CATX
    Perspective Therapeutics
    19.06x -- -- -$15.1M
  • Which has Higher Returns ARAY or HAE?

    Haemonetics has a net margin of -3.89% compared to Accuray's net margin of 9.79%. Accuray's return on equity of -35.94% beat Haemonetics's return on equity of 13.51%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    33.95% -$0.04 $215.5M
    HAE
    Haemonetics
    54.25% $0.66 $2.1B
  • What do Analysts Say About ARAY or HAE?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 187.56%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 41.87%. Given that Accuray has higher upside potential than Haemonetics, analysts believe Accuray is more attractive than Haemonetics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    HAE
    Haemonetics
    3 2 0
  • Is ARAY or HAE More Risky?

    Accuray has a beta of 1.468, which suggesting that the stock is 46.785% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

  • Which is a Better Dividend Stock ARAY or HAE?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or HAE?

    Accuray quarterly revenues are $101.5M, which are smaller than Haemonetics quarterly revenues of $345.5M. Accuray's net income of -$4M is lower than Haemonetics's net income of $33.8M. Notably, Accuray's price-to-earnings ratio is -- while Haemonetics's PE ratio is 32.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.48x versus 2.95x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.48x -- $101.5M -$4M
    HAE
    Haemonetics
    2.95x 32.41x $345.5M $33.8M
  • Which has Higher Returns ARAY or XTNT?

    Xtant Medical Holdings has a net margin of -3.89% compared to Accuray's net margin of -17.98%. Accuray's return on equity of -35.94% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    33.95% -$0.04 $215.5M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About ARAY or XTNT?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 187.56%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 381.39%. Given that Xtant Medical Holdings has higher upside potential than Accuray, analysts believe Xtant Medical Holdings is more attractive than Accuray.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is ARAY or XTNT More Risky?

    Accuray has a beta of 1.468, which suggesting that the stock is 46.785% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

  • Which is a Better Dividend Stock ARAY or XTNT?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or XTNT?

    Accuray quarterly revenues are $101.5M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Accuray's net income of -$4M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Accuray's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.48x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.48x -- $101.5M -$4M
    XTNT
    Xtant Medical Holdings
    0.55x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Marvell Stock Up?
Why Is Marvell Stock Up?

Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…

Why Is General Electric Stock Going Up?
Why Is General Electric Stock Going Up?

General Electric Company, doing business these days as GE Aerospace…

Where Will Cisco Systems Stock Be in 10 Years?
Where Will Cisco Systems Stock Be in 10 Years?

Cisco Systems, Inc. (NASDAQ:CSCO) has enjoyed its position as a…

Stock Ideas

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Sell
44
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
1
IONQ alert for Jan 9

IonQ [IONQ] is down 38.82% over the past day.

Sell
40
QMCO alert for Jan 9

Quantum [QMCO] is down 30.08% over the past day.

Sell
47
MATW alert for Jan 9

Matthews International [MATW] is up 14.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock